Neurological symptoms of COVID-19

Adriana Wawer; Agnieszka Piechal

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

Otwarty dostęp

4/2020
vol. 36

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł przeglądowy

Objawy neurologiczne w przebiegu COVID-19

Adriana Wawer

¹

,

Agnieszka Piechal

^{1, 2}

Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT, Medical University of Warsaw

2nd Department of Neurology, Institute of Psychiatry and Neurology in Warsaw

Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (4), 285–296

Data publikacji online: 2021/12/06

Plik artykułu:

- 02R_IPiN_FARM_2020-4D_AKC.pdf [0.20 MB]

Pobierz cytowanie

1. Abdennour L, Zeghal C, Dème M, Puybasset L. [Interaction brain-lungs]. Ann Fr Anesth Reanim 2012; 31, e101-7.

2. Al-Obaidi MM, Bahadoran A, Wang S, Manikam R, Raju CHS, Sekaran S. Disruption of the blood brain barrier is vital prop erty of neurotropic viral infection of the central nervous system. Acta Virol 2018; 62, 16-27.

3. Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, San toro P et al. Guillain-Barré syndrome related to COVID-19 infection. 2020; 7, e741

4. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mech anisms. ACS Chem Neurosci 2020; 11, 995-998.

5. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. Front Cell Neurosci 2018; 12.

6. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahla wat A, Narayanaswami P. COVID-19-associated Guillain-Bar ré syndrome: The early pandemic experience. Muscle Nerve 2020 Jul 17:10.1002/mus.27024.

7. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi 2020; 36, E005.

8. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses 2019; 12, 14.

9. Dobbs MR. Toxic encephalopathy. Seminars in neurology, 2011. © Thieme Medical Publishers, 184-193.

10. Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. Journal of Thrombosis and Thrombolysis 2020.

11. Elkind MS. Why now? Moving from stroke risk factors to stroke triggers. Curr Opin Neurol 2007; 20, 51-57.

12. Ellul M, Solomon T. Acute encephalitis–diagnosis and man agement. Clinical Medicine 2018; 18, 155.

13. EMA 2020. Treatments and vaccines for COVID-19. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treat ments-vaccines-covid-19#remdesivir-section [Dostęp: 16.07.2020].

14. Enquist LW. Five questions about viral trafficking in neurons. PLoS Pathog 2012; 8, e1002472-e1002472.

15. FDA 2020. Coronavirus (COVID-19) Update: FDA Issues Emergen cy Use Authorization for Potential COVID-19 Treatment. https://www.fda.gov/news-events/press-announcements/coronavi rus-covid-19-update-fda-issues-emergency-use-authoriza tion-potential-covid-19-treatment [Dostęp: 16.07.2020].

16. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin 2020.

17. Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology 2020.

18. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L et al. Self-reported olfactory and taste disorders in SARS--CoV-2 patients: a cross-sectional study. Clin Infect Dis 2020.

19. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med2005; 202, 415-24.

20. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res 2020; 7, 1-10.

21. Hopkins C, Surda P, Whitehead E, Kumar BN. Early recovery following new onset anosmia during the COVID-19 pande mic – an observational cohort study. J Otolaryngol Head Neck Surg 2020; 49, 26.

22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395, 497-506.

23. Kaya Y, Kara S, Akinci C, Kocaman AS. Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: Case report. J Neurol Sci 2020; 413, 116858.

24. Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH et al.Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol 2017; 13, 227-233.

25. Klein RS, Garber C, Howard N. Infectious immunity in the central nervous system and brain function. Nat Immunol2017; 18, 132-141.

26. Klok FA, Kruip M, Van Der Meer N, Arbous M, Gommers D, Kant K et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis research 2020.

27. Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell Host Microbe 2013; 13, 379-393.

28. Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S et al. Multicenter evaluation of BioFire FilmArray me ningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol2016; 54, 2251-2261.

29. Li Y, Fu L, Gonzales DM, Lavi E. Coronavirus neurovirulence correlates with the ability of the virus to induce proinflam matory cytokine signals from astrocytes and microglia. J Virol 2004; 78, 3398-406.

30. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis research 2020.

31. Mahammedi A, Saba L, Vagal A, Leali M, Rossi A, Gaskill M et al. Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study. Radiology 2020; 0, 201933.

32. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; 382, 2431-2440.

33. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020.

34. Marinosci A, Landis BN, Calmy A. Possible link between anosmia and COVID-19: sniffing out the truth. Eur Arch Otorhinolaryngol 2020, 1-2.

35. Maximova OA, Pletnev AG. Flaviviruses and the Central Nervous System: Revisiting Neuropathological Concepts. Annu Rev Virol 2018; 5, 255-272.

36. Mehta P, Mcauley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395, 1033-1034.

37. Michalicova, A., Bhide, K., Bhide, M.,Kováč, A. How viruses in filtrate the central nervous system. Acta Virol2017; 61, 393-400.

38. Miller AJ, Arnold AC. The renin–angiotensin system in car diovascular autonomic control: recent developments and clinical implications. Clin Auton Res 2019; 29, 231-243.

39. Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo-Putze G, Martín A et al. Frequency of five unusual presentations in patients with COVID-19: results of the UMC-19-S1. Epidemi ology and Infection 2020; 148, e189.

40. Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M. Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand Suppl 2007; 186, 45-56.

41. Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tou si A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol 2020.

42. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Ta kamino J et al. A first case of meningitis/encephalitisassociated with SARS-Coronavirus-2. Int J Infect Dis 2020; 94, 55-58.

43. Munz M, Wessendorf S, Koretsis G, Tewald F, Baegi R, Krämer S et al. Acute transverse myelitis after COVID-19 pneumonia. Journal of Neurology 2020, 1.

44. Mustafá YM, Meuren LM, Coelho SVA, De Arruda LB. Path ways Exploited by Flaviviruses to Counteract the Blood Brain Barrier and Invade the Central Nervous System. Front Microbiol 2019; 10, 525-525.

45. National Institutes of Health 2020. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treat ment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ [Dostęp: 16.07.2020].

46. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med 2020; 382, e60.

47. Padroni, M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Ru meileh S, Piscaglia MG et al. Guillain-Barré syndrome fol lowing COVID-19: new infection, old complication? Journal of neurology 2020, 1.

48. Perlman S, Evans G, Afifi A. Effect of olfactory bulb ablation on spread of a neurotropic coronavirus into the mouse brain. J Exp Med 1990; 172, 1127-32.

49. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020, 201187.

50. Recovery 2020. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory com plications of COVID-19. https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-compli cations-of-covid-19 [Dostęp: 16.07.2020].

51. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382, 2441-2448.

52. Rothstein A, Oldridge O, Schwennesen H, Do D, Cucchiara BL. Acute Cerebrovascular Events in Hospitalized COVID-19 Patients. Stroke 2020; 51, e219-e222.

53. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis2014; 29, 301-306.

54. Sarma D, Bilello LAA. Case Report of Acute Transverse Mye litis Following Novel Coronavirus Infection. Clinical Practice Cases in Emergency Medicine 2020.

55. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16, 69.

56. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Journal of Clinical Neuroscience 2020; 76, 233-235.

57. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E et al. COVID-19-Related Severe Hypercoagulability in Pa tients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost 2020; 120, 998-1000.

58. Swanson II PA, Mcgavern DB. Viral diseases of the central nervous system. Curr Opin Virol 2015; 11, 44-54.

59. Tauber SC, Eiffert H, Brück W, Nau R. Septic encephalopathy and septic encephalitis. Expert Rev Anti Infect Ther 2017; 15, 121-132.

60. Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ 2020; 369, m2263.

61. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES, Tu TM, Sharma VK, Yeo LLL, Chan BPL, Tan BYQ. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020 Jul 13: 1-9.

62. Tsai L, Hsieh S, Chang Y. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan2005; 14, 113.

63. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopepti dase to SARS virus receptor. Trends Pharmacol Sci 2004; 25, 291-294.

64. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv 2020.

65. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama2020a; 323, 1061-1069.

66. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020b; 92, 568-576.

67. Warren-Gash C, Blackburn R, Whitaker H, Mcmenamin J, Hayward AC. Laboratory-confirmed respiratory infec tions as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked data sets from Scotland. Eur Respir J 2018; 51, 1701794.

68. WHO, 2020a. https://www.who.int/docs/default-source/coronaviruse/situation-reports/wou-18-september-2020-c leared.pdf?sfvrsn=be6111c8_2 [Dostęp: 20.09.2020].

69. WHO, 2020b. “Solidarity” clinical trial for COVID-19 treatments. https://www.who.int/emergencies/diseases/novel-coronavi rus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments [Dostęp: 16.07.2020].

70. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367, 1260-1263.

71. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L et al. Nerv ous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020; 87, 18-22.

72. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8, 420-422.

73. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K et al. SARS2-CoV-2 and stroke in a New York healthcare system. Stroke 2020, STROKEAHA. 120.030335.

74. Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C et al. Angioten sin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014; 4, 7027.

75. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospec tive, observational study. Lancet Respir Med 2020a.

76. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G et al. The dead ly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020b, 102434.

77. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun 2020a.

78. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020b; 80, 607-613.

79. Young GB. Encephalopathy of infection and systemic inflam mation. J Clin Neurophysiol 2013; 30, 454-461.

80. Zachariadis A, Tulbu A, Strambo D, Dumoulin A, Di Virgilio G. Transverse myelitis related to COVID-19 infection. Journal of neurology 2020, 1-3.

81. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syn drome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology 2020; 19, 383-384.

82. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardi ovascular system. Nat Rev Cardiol 2020; 17, 259-260.

Objawy neurologiczne w przebiegu COVID-19

Adriana Wawer 1 , Agnieszka Piechal 1, 2

Adriana Wawer

¹

,

Agnieszka Piechal

^{1, 2}